Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 6960

Sort by

Sort Order Select

Journal Articles

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Saad Z. Usmani, MDMBBS, Hang Quach, MD, María-Victoria Mateos, Ola Landgren, MD PhD, Xavier Leleu, MD PhD, David S. Siegel, Katja Weisel, Hui Yang, Zandra K. Klippel, MD, Anita Zahlten-Kumeli, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_2): LBA-6.

https://doi.org/10.1182/blood-2019-132629

Published: 2019

Journal Articles

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Ilaria Iacobucci, PhD, Manja Meggendorfer, PhD, Niroshan Nadarajah, Stanley Pounds, PhD, Lei Shi, PhD, Chunxu Qu, PhD, Constance Baer, PhD, Claudia Haferlach, MD, Wolfgang Kern, MD, Charles G. Mullighan, MBBS, MD, Torsten Haferlach, MD

Blood (2019) 134 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2019-132746

Published: 2019

Journal Articles

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Blood (2019) 134 (Supplement_2): LBA-3.

https://doi.org/10.1182/blood-2019-132405

Published: 2019

Journal Articles

CYT-0853, a Novel RAD51 Inhibitor, Modulates Immunoregulatory B-Lymphocytes

Tamar Aprahamian, PhD, ED Keniston, Jane Branca, Muneer G Hasham, PhD, Melinda Day, PhD, Kevin Mills, PhD

Blood (2019) 134 (Supplement_1): 2330.

https://doi.org/10.1182/blood-2019-131311

Published: 2019

Journal Articles

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice

Frank Del Greco, MBA, Linda Neuman, MD, Howard Levy, PhD MBBChir, Jill Reckless, Tom Knudsen, PhD DVM, Grant E. Blouse, PhD

Blood (2019) 134 (Supplement_1): 2420.

https://doi.org/10.1182/blood-2019-128971

Published: 2019

Journal Articles

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

Vincent P. Diego, PhD, Bernadette W. Luu, B.S., M.T. (CLS), Afshin Ameri, MD, Meera B. Chitlur, MD, Marcio A. Almeida, PhD, Karin Haack, PhD, Satish Kumar, PhD, Long V. Dinh, PhD, Henry Mead, M.B.A., M.P.H., Jerry S. Powell, MD, Miguel A. Escobar, MD, Raja Rajalingam, PhD, Sarah Williams-Blangero, PhD, Carol K. Kasper, MD, Laura Almasy, PhD, Shelley Cole, PhD, John Blangero, PhD, Tom E. Howard, MD, PhD

Blood (2019) 134 (Supplement_1): 2393.

https://doi.org/10.1182/blood-2019-132218

Published: 2019

Journal Articles

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Kwanza Price, MPH, Zhun Cao, PhD, Craig Lipkin, Scott Robinson, Deborah Ann Profant, PhD

Blood (2019) 134 (Supplement_1): 2213.

https://doi.org/10.1182/blood-2019-127075

Published: 2019

Journal Articles

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

John Porter, Maria Domenica Cappellini, MD, Thomas Coates, MD, Olivier Hermine, Vip Viprakasit, MD DPhil, Ersi Voskaridou, Hong Keng Liew, Silverio Perrotta, Abderrahim Khelif, Antonis Kattamis, Abderrahmane Laadem, Jeevan K. Shetty, Wen-Ling Kuo, Dimana Miteva, Tatiana Zinger, Peter G. Linde, Daniel Sinsimer, Ali Taher

Blood (2019) 134 (Supplement_1): 2245.

https://doi.org/10.1182/blood-2019-122561

Published: 2019

Journal Articles

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Michael Callaghan, MD, Benjamin Trzaskoma, MS, Richard H. Ko, MD, Lucy Lee, PharmD, Anisha M. Patel, PhD, Eunice Tzeng, PharmD, Michelle Lynn Shah, PharmD, Tiffany Y. Chang, MD MAS, Markus Niggli, PhD, Christophe Dhalluin, PhD, Johnny Mahlangu, MMed, FCPath

Blood (2019) 134 (Supplement_1): 2395.

https://doi.org/10.1182/blood-2019-123654

Published: 2019

Journal Articles

Estimating the Burden of Intracranial Hemorrhage in Persons with Hemophilia A using Administrative Claims Data

Arash Mahajerin, MD MS, Anisha M. Patel, PhD, Erru Yang, MS, Chinelo C. Orji, MS, Richard H. Ko, MD

Blood (2019) 134 (Supplement_1): 2398.

https://doi.org/10.1182/blood-2019-123713

Published: 2019

Journal Articles

Mitapivat (AG-348), an Oral PK-R Activator, in Adults with Non-Transfusion Dependent Thalassemia: A Phase 2, Open-Label, Multicenter Study in Progress

Kevin H. M. Kuo, MDMSc,FRCPC, D. Mark Layton, MB BS, Katrin Uhlig, MD MS, Megan Lynch, MSN, NP, Li Liu, PhD, Elliott P. Vichinsky, MD

Blood (2019) 134 (Supplement_1): 2249.

https://doi.org/10.1182/blood-2019-123113

Published: 2019

Journal Articles

Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers

Kishor Devalaraja-Narashimha, PhD DVM, Yan G Ni, PhD, Cong Huang, Ming-Dauh Wang, PhD, Umesh Chaudhari, MD, Srinivasa Prasad, PhD, Olivier Harari, MD PhD, Andrew J Rankin, PhD, Lori Morton, PhD, Jonathan Weyne, MD

Blood (2019) 134 (Supplement_1): 2278.

https://doi.org/10.1182/blood-2019-129865

Published: 2019

Journal Articles

Quality of Life (QoL) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Treated with Polatuzumab Vedotin Plus Rituximab in the ROMULUS Study

Per-Olof Thuresson, MSc, MPharm, Brittany Gentile, PhD, David Ramies, MD, Aino Launonen, MSc, Franck Morschhauser, MD

Blood (2019) 134 (Supplement_1): 4767.

https://doi.org/10.1182/blood-2019-123688

Published: 2019

Journal Articles

The Unforeseen Medical and Business Challenges Found When Integrating Abstracted Data from Disparate EHR Systems While Building the Curecloud Direct-to-Patient Multiple Myeloma Registry

Steven E. Labkoff, MD, Shaadi Mehr, PhD, Christopher Williams, Daniel Auclair, Paul A. Giusti, MBA, Kathy E. Giusti, MBA, Stuart L. Goldberg, MD, Kevin M Keogh, Andrew J. Belli, MPH, Andrew D Norden, MDMPH MBA

Blood (2019) 134 (Supplement_1): 4736.

https://doi.org/10.1182/blood-2019-130276

Published: 2019

Journal Articles

Mitapivat (AG-348) in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (ACTIVATE) in Progress

Eduard J. van Beers, MD PhD, Malia P. Judge, BS, RN, Lei Hua, PhD, Chris Mix, MD

Blood (2019) 134 (Supplement_1): 4791.

https://doi.org/10.1182/blood-2019-123100

Published: 2019

Journal Articles

A Discrete Event Simulation Model to Evaluate the Impact of Treatment Sequences on Long-Term Patient Outcomes in Multiple Myeloma (MM)

Jinan Liu, PhD, Daniel Moldaver, PhD, Xinmei Zhu, PhD, Allen Zhou, BASc, Eric M Maiese, PhD, Sarah Hollmann, M.Biotech

Blood (2019) 134 (Supplement_1): 4737.

https://doi.org/10.1182/blood-2019-123804

Published: 2019

Journal Articles

Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia

Ivy Altomare, MD, Vadim V. Markovtsov, PhD, Leslie Todd, Dheepika Weerasinghe, PhD, Robert P. Numerof, PhD, Sandy Tong, MD, Esteban Masuda, PhD, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 4889.

https://doi.org/10.1182/blood-2019-126558

Published: 2019

Journal Articles

Impact of Modified Thalidomide Dosing in Bortezomib/Thalidomide/Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible: A Matching-Adjusted Indirect Comparison

Pieter Sonneveld, Maria-Victoria Mateos, MD PhD, Adrián Alegre, MD, Thierry Facon, MD, Cyrille Hulin, MD, Mahmoud Hashim, Talitha Vincken, Tobias Kampfenkel, MD, Sarah Cote, Philippe Moreau, MD

Blood (2019) 134 (Supplement_1): 4739.

https://doi.org/10.1182/blood-2019-122775

Published: 2019

Journal Articles

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Mohammad O Hussaini, MD, Jaya Srivastava, PhD, Lik Wee Lee, PhD, Taiga Nishihori, MD, Bijal Shah, MD, Melissa Alsina, MD, Rachid Baz, MD, Javier Pinilla Ibarz, MD PhD, Kenneth H. Shain, MD PhD

Blood (2019) 134 (Supplement_1): 4654.

https://doi.org/10.1182/blood-2019-129846

Published: 2019

Journal Articles

Clinical Practice Patterns for Hydroxyurea Initiation in Young Children with Sickle Cell Disease

Anna M Hood, PhD, Yolanda Johnson, MLS, Cara Nwankwo, BA, Lisa M Shook, MA, Aimee K Hildenbrand, PhD, Allison A. King, MD MPH, PhD, Kim Smith-Whitley, MD, Sherif M. Badawy, MD, Alexis A Thompson, MD MPH, Susan E Creary, MD, Connie M. Piccone, MD, Lynne D. Neumayr, Jean L. Raphael, MD MPH, Amber M Yates, MD, Sohail Rana, MD, Steven K Reader, PhD, Emily Riehm Meier, MD MSHS, Amy Sobota, MD MPH, Lori E. Crosby, PhD

Blood (2019) 134 (Supplement_1): 4713.

https://doi.org/10.1182/blood-2019-124835

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor (NCT03158688)

Integrated Transcriptomic and Genomic Sequencing Identifies Prognostic Constellations of Driver Mutations in Acute Myeloid Leukemia and Myelodysplastic Syndromes

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

CYT-0853, a Novel RAD51 Inhibitor, Modulates Immunoregulatory B-Lymphocytes

Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports on-Demand Treatment in Hemophilia a Mice

On the Role of F8 Sequence Mismatch and Class-II Human Leukocyte Antigen Binding in the Development of Neutralizing Antibodies ("Inhibitors") Directed Against Therapeutic Factor VIII Proteins (tFVIIIs): Evidence from the PATH Study

A Descriptive Study on Healthcare Utilization and Costs in Secondary Acute Myeloid Leukemia Patients Treated with CPX-351 Versus Those Treated with 7+3

Effects of Luspatercept on Iron Overload and Impact on Responders to Luspatercept: Results from the BELIEVE Trial

Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience

Estimating the Burden of Intracranial Hemorrhage in Persons with Hemophilia A using Administrative Claims Data

Mitapivat (AG-348), an Oral PK-R Activator, in Adults with Non-Transfusion Dependent Thalassemia: A Phase 2, Open-Label, Multicenter Study in Progress

Pozelimab, a Human Antibody Against Complement Factor C5, Demonstrates Robust Inhibition of Alternative Complement Activity Both in Normal Human Serum and in Phase I Normal Healthy Volunteers

Quality of Life (QoL) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Treated with Polatuzumab Vedotin Plus Rituximab in the ROMULUS Study

The Unforeseen Medical and Business Challenges Found When Integrating Abstracted Data from Disparate EHR Systems While Building the Curecloud Direct-to-Patient Multiple Myeloma Registry

Mitapivat (AG-348) in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study (ACTIVATE) in Progress

A Discrete Event Simulation Model to Evaluate the Impact of Treatment Sequences on Long-Term Patient Outcomes in Multiple Myeloma (MM)

Potential Anti-Thrombotic Effect without Accompanying Hemorrhage with Fostamatinib Use in Patients with Immune Thrombocytopenia

Impact of Modified Thalidomide Dosing in Bortezomib/Thalidomide/Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible: A Matching-Adjusted Indirect Comparison

Moffitt Cancer Center 2-Year Single-Institution Experience with Next-Generation Sequencing Minimal Residual Disease Detection: Clinical Utility, Application, and Correlation with Outcomes in Plasma Cell and Lymphoid Malignancies

Clinical Practice Patterns for Hydroxyurea Initiation in Young Children with Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only